Search results for "Highlights"


 
Results 81 - 90 of about 446 for "Highlights".
Sort by: Relevance | Newest | Oldest

Glucose-lowering treatment after type 2 diabetes diagnosis differed by race/ethnicity

Among 77,199 patients in a U.S. health system with a new diagnosis of diabetes from 2005 to 2016, 47% started a diabetes medication within 12 months. Prevalence differed by race and ethnicity, although the difference was mitigated by variation in HbA1c levels.
https://diabetes.acponline.org/archives/2022/08/12/3.htm
12 Aug 2022

SGLT-2 inhibitors reduce cardiac events, mortality compared to DPP-4 inhibitors

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors were associated with lower risk of cardiovascular events compared to dipeptidyl peptidase-4 (DPP-4) inhibitors but higher risk of genital infections and diabetic ketoacidosis, a retrospective study found.
https://diabetes.acponline.org/archives/2023/02/10/1.htm
10 Feb 2023

Guaranteeing adequate carbs before postpartum oral glucose tolerance testing may not be necessary

An analysis of data from two prospective studies found no relationship between carbohydrate intake in the day or days before testing and glucose level 120 minutes after oral glucose tolerance testing.
https://diabetes.acponline.org/archives/2023/05/12/1.htm
12 May 2023

Recent articles address federal diabetes programs, type 1 diabetes care

The National Clinical Care Commission made 39 recommendations for improving federal diabetes programs, and the latest In the Clinic article offered advice on diagnosing and treating type 1 diabetes.
https://diabetes.acponline.org/archives/2022/03/11/6.htm
11 Mar 2022

High-sensitivity C-reactive protein level predicted mortality risk in recent-onset type 2 diabetes

While high-sensitivity C-reactive protein was a good predictor of mortality, C-peptide levels were more closely associated with cardiovascular events, and having high levels of both was associated with increased risk of either outcome, a prospective study in Denmark found.
https://diabetes.acponline.org/archives/2023/04/14/1.htm
14 Apr 2023

Interventions uncommon for prediabetes in primary care

A U.S. retrospective study found that while 63.4% of prediabetes patients had repeated glycemic testing over one year of follow-up, 10.4% had a primary care visit with a coded diagnosis of prediabetes, 1.0% were referred for nutrition services, and 5.4% were prescribed metformin.
https://diabetes.acponline.org/archives/2022/03/11/2.htm
11 Mar 2022

Obesity increasing in type 1 diabetes, associated with higher risk for chronic kidney disease

Obesity in type 1 diabetes rose from 2004 to 2018, and patients with type 1 had a higher adjusted prevalence of low estimated glomerular filtration rate and albuminuria than those with type 2, an analysis of one health system found.
https://diabetes.acponline.org/archives/2022/02/11/3.htm
11 Feb 2022

Severe insulin-resistant diabetes associated with better metabolic surgery outcomes

Patients with severe insulin-resistant diabetes had better outcomes after metabolic surgery than those with mild obesity-related diabetes or severe insulin-deficient diabetes, both in terms of type 2 diabetes remission and renal function, with no additional surgical risk.
https://diabetes.acponline.org/archives/2022/03/11/3.htm
11 Mar 2022

Nearly one-third of patients were nonadherent to newly prescribed SGLT-2 inhibitors, GLP-1 receptor agonists

Factors associated with not filling a new prescription for a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist included older age, Black race, male sex, certain comorbid conditions, and having a primary care clinician prescribe the drug, a study found.
https://diabetes.acponline.org/archives/2022/02/11/2.htm
11 Feb 2022

Choice of SGLT-2 inhibitors, GLP-1 receptor agonists should be based on individual risk

A meta-analysis comparing sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists found differing effects, including that the SGLT-2 inhibitors affected heart failure outcomes while GLP-1 receptor agonists reduced stroke risk.
https://diabetes.acponline.org/archives/2021/02/12/3.htm
12 Feb 2021

Result Page: Prev   4   5   6   7   8   9   10   11   12   13   Next